Thermo Fisher Scientific (NYSE:TMO) is a leader in scientific instruments, reagents, and software services. With a $167.89 billion market cap and a P/E ratio of 24.7, the stock appears undervalued.
In January 2026, management changes occurred. COO Michel Lagarde and EVP Frederick Lowery departed. Gianluca Pettiti was promoted to COO.
In October 2025, Thermo Fisher announced its intention to acquire Clario for approximately $9 billion. This acquisition enhances clinical trial capabilities with AI solutions.
Q3 2025 results showed strength, with Analytical Instruments delivering 4% core growth. The company maintains a conservative guidance approach.
Analysts note improving industry conditions and normalized biopharma spending. The company's strategic acquisitions and strong market position support growth.
This analysis covers October 2025 to April 2026. Bond.az provides insights for your investment decisions.
